The findings unravel oncogenic mechanisms in HG-ESS and provide rationales for targeting RAF/MEK/MAPK and Hippo-YAP/TAZ signaling pathways as therapeutic approaches in HG-ESS with YWHAE-NUTM2. Here, RAF1 is linked to endometrioid stromal sarcoma.